@article{JGO116886,
author = {Eonwoo Shin and Hyo Sang Lee and Dae-Woon Eom and Jae Young Kwak and Kwan Mo Yang and Ho-Suk Oh and Sehee Kim and Chang Sik Yu},
title = {Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II–III colorectal cancer},
journal = {Journal of Gastrointestinal Oncology},
volume = {17},
number = {2},
year = {2026},
keywords = {},
abstract = {Clinicopathological risk factors in non-metastatic colorectal cancer provide prognostic information but have limited ability to identify patients who benefit from specific adjuvant chemotherapy regimens. Pyruvate kinase M2 (PKM2), a key regulator of aerobic glycolysis and tumor proliferation, has been linked to chemotherapy sensitivity in a regimen-dependent manner. This study evaluated intratumoral PKM2 expression as a predictive biomarker for the effectiveness of oxaliplatin-based adjuvant chemotherapy in stage II/III colorectal cancer.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/116886}
}